ClinicalTrials.gg
Active, not recruitingNCT06577935ARTEMISUpdated Feb 10, 2026

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

A Phase 2 interventional study of AGA2118 and Placebo in Postmenopausal Osteoporosis, sponsored by Angitia Biopharmaceuticals. Active, not recruiting at 23 sites in 4 countries. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Angitia Biopharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
379
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Osteoporosis, Postmenopausal with a site in Argentina — none open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · Argentina.

Enrollment
14th of 17
379 · median 1,139
Started
2024
the only one that year
Phase 2
Only one
of the 17
Registered
17th of 17
by date
Lead sponsor
1 of 17
Angitia Biopharmaceuticals

Among the 17 studies in Osteoporosis, Postmenopausal with a site in Argentina, this one is the 14th largest by enrollment, is the only one that started in 2024, is the only one in phase 2, and was the 17th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 17 studies in Osteoporosis, Postmenopausal with a site in Argentina is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Osteoporosis, Postmenopausal with a site in Argentina as a file.
02

Study summary

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.

Read the detailed description

This Phase 2 dose-finding study will evaluate the safety, tolerability, and efficacy of AGA2118 at a range of dosing regimens in postmenopausal women with low BMD at the lumbar spine, total hip, or femoral neck and no prior history of fragility fractures.

This study includes a 12 month blinded treatment phase where participants will be randomized 1:1:1:1:1:1:1 to receive double-blind dosing regimens of AGA2118 or placebo. At Month 12, participants who have completed the double-blind portion of the study will continue on to a 12 month open-label period where they will be re-randomized based on their prior dosing regimen to either continue their current dosing regimen, receive a new dosing regimen, or discontinue treatment and be actively surveilled throughout Months 12 to 24.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Osteoporosis
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, women age ≥ 55 to ≤ 80.
  • BMD T-score of ≤ -2.5 to > -3.5 at the lumbar spine, total hip, or femoral neck.

Exclusion criteria

Exclusion Criteria:

  • History of vertebral fracture, or fragility fracture of the wrist, humerus, proximal femur, or pelvis.
  • Vitamin D deficiency.
  • Known intolerance to calcium or vitamin D supplements.
  • Untreated hyper- or hypothyroidism.
  • Current hyper- or hypoparathyroidism.
  • Elevated transaminases.
  • Significantly impaired renal function.
  • Current hypo- or hypercalcemia.
  • Positive for , virus, or surface antigen.
  • within the last 5 years.
  • Diagnosis of a familial cancer syndrome or known genetic mutation that increases risk of cancer.
  • Myocardial infarction or stroke within the past 12 months.
  • Use of agents affecting bone metabolism.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
379 participants (actual)

Study arms

  • Experimental
    AGA2118 Dose Regimen 1

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Experimental
    AGA2118 Dose Regimen 2

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Experimental
    AGA2118 Dose Regimen 3

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Experimental
    AGA2118 Dose Regimen 4

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Experimental
    AGA2118 Dose Regimen 5

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Experimental
    AGA2118 Dose Regimen 6

    AGA2118 selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Drug: AGA2118

  • Placebo comparator
    Placebo Regimen

    Placebo selected dose Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24.

    Other: Placebo

Interventions

  • Subcutaneous injection

  • OtherPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent change from Baseline to Month 12 in lumbar spine bone mineral density

    To determine the effect of treatment with AGA2118 versus placebo at Month 12 on the percent change from Baseline in bone mineral density at the lumbar spine in postmenopausal women with low bone mineral density

    Time frame: 12 months

Secondary outcomes

  1. Percent change from Baseline to Months 3 and 6 in lumbar spine, total hip, femoral neck, and one-third distal radius bone mineral density

    To evaluate the effect of treatment with AGA2118 versus placebo at different timepoints on percent change from Baseline in bone mineral density at the lumbar spine, total hip, femoral neck, and one-third distal radius

    Time frame: 3 and 6 months

  2. Percent change from Baseline to Month 12 in total hip, femoral neck, and one-third distal radius bone mineral density

    To evaluate the effect of treatment with AGA2118 versus placebo at different timepoints on percent change from Baseline in bone mineral density at the lumbar spine, total hip, femoral neck, and one-third distal radius

    Time frame: 12 months

  3. Percent change from Baseline to Months 1, 3, 6, 9, and 12 in P1NP and CTX-1

    To evaluate the effect of treatment with AGA2118 versus placebo at different time points on percent change from Baseline in P1NP and CTX-1

    Time frame: 1, 3, 6, 9, and 12 months

  4. Incidence of new clinical fractures (vertebral and nonvertebral) between Baseline and Month 12

    To evaluate the incidence of new clinical fractures (vertebral and nonvertebral) from Baseline to Month 12

    Time frame: 12 months

Other outcomes

  1. Assessment of TEAEs (collection and documentation of all adverse events occurring during the study)

    Time frame: Baseline to 24 months

  2. Number of participants who develop anti-AGA2118 antibodies

    To assess the formation of anti-AGA2118 antibodies

    Time frame: Baseline to 24 months

  3. Evaluation of AGA2118 observed serum concentration levels for the AGA2118 treatment groups at Week 1 post-treatment and trough levels prior to dosing

    To characterize the pharmacokinetic parameters of the different AGA2118 doses

    Time frame: Baseline to 24 months

07

Study locations

23 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 29, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06577935
Lead sponsor
Angitia Biopharmaceuticals
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Oct 31, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Ricardo Dent-Acosta, MD
study director · Angitia Incorporated Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGA2118

Start the discussion